• Policy
• “Calling for promotion of substitute drug dispensation“
• by Lee, Jeong-Hwan Mar 13, 2024 05:32am

• Company
• Yuhan Corp and BMS will copromote Sotyktu and Zeposia
• by Nho, Byung Chul Mar 13, 2024 05:32am

• Policy
• Companies with superior CP ratings get reduced fines
• by Lee, Jeong-Hwan Mar 13, 2024 05:32am

• Policy
• ‘A multifaceted approach to reimburse high-priced drugs'
• by Lee, Jeong-Hwan Mar 13, 2024 05:32am

• Company
• Bosulif prescriptions now available at general hospitals
• by Eo, Yun-Ho Mar 13, 2024 05:32am

• Opinion
• [Reporter’s View] Need momentum to boost investments
• by Kim, Jin-Gu Mar 12, 2024 05:49am

• Company
• Quadrivalent meningococcal vaccine MenQuadfi approved
• by Eo, Yun-Ho Mar 12, 2024 05:49am

• Opinion
• [Reporter’s View] Potential drawbacks of expanding RSAs
• by Lee, Tak-Sun Mar 12, 2024 05:49am

• Company
• Ilaris’s reimb again at a standstill… bumpy road ahead
• by Eo, Yun-Ho Mar 12, 2024 05:48am

• Company
• SK Bioscience breaks ground on vaccine plant expansion
• by Chon, Seung-Hyun Mar 11, 2024 05:55am